Company Overview and News

0
Arrow Minerals confirms major gold prospect with aircore drilling

2018-05-16 proactiveinvestors.com.au
Arrow Minerals Ltd (ASX:AMD) has intersected bedrock gold mineralisation in multiple holes at its T8 prospect within the Strickland Gold Project in Western Australia.
ELKMF GOR BRRKF BRB

1
Gold Road discovers high gold grades of up to 17.45g/t at Southern Yamarna

2018-05-07 australianmining.com.au
Mid-tier miner and explorer Gold Road Resources has confirmed multiple high-grade gold results from its South Yamarna tenements, part of the Yamarna Belt in Yilgarn Craton, Western Australia, returning results of up to 17.45 grams per tonne (g/t).
ELKMF GFI.WI GOR GFI GFIOF

1
Heavy rainfall delays first gold at Gruyere

2018-04-24 australianmining.com.au
Poor weather has forced the Gruyere gold joint venture partners to delay their plan for first gold at the Western Australian development.
ELKMF GFI.WI GOR GFI GFIOF

0
Cost increase at Gruyere project

2018-04-23 businessnews.com.au
Gold Road Resources has announced cost increases and schedule delays due to recent heavy rainfall at its half-owned Gruyere gold project near Laverton.
ELKMF GOR

1
Gold Road starts work on $23m greenfields campaign

2018-04-06 australianmining.com.au
Gold Road Resources has launched its $23 million 2018 greenfields exploration drilling campaign in Western Australia.
ELKMF GFI.WI GOR GFI GFIOF

0
Gold Road and Cygnus form JV at WA gold project

2018-03-22 australianmining.com.au
Cygnus Gold has announced that it has entered into a joint venture (JV) agreement with Gold Road Resources over the Yandina project in the southern wheatbelt of Western Australia.
ELKMF GOR

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to ASX:GOR / GOLD ROAD RESOURCES LIMITED on message board site Silicon Investor.

Gorilla and King Portfolio Candidates Gorilla and King lists
Gorilla Game Investing in the eWorld Gorilla and King Portfolio candidates - Moderated
New Gold Stock FGLD and Gordon Lee Why is Gore Trying to Steal the Presidency?
GRC: Gorman-Rupp Company Dave Goreu0027s Trades That Make Sense
ALGORE THE POWERFUL Al Gore Traitor or Fool